MiMedx
MDXG
4.55
-0.06
-1.30%
MiMedx
US · MDXG
#3541 by market cap
4.55
-0.06
-1.30%
Live - 5344 symbols - heartbeat 526s ago
· 2026-10-08 09:59
Pre-market
4.58
-0.65%
After-hours
4.61
0.00%
- Market cap
- 664.00M
- P/E (TTM)i
- 113.75
- P/Bi
- 3.07
- EPSi
- 0.32
- Div yieldi
- 0.00%
- 52W posi
- 31%
Reader sentiment
Are you bullish or bearish on MDXG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.04, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +19.99% YoY
Margins
- Gross margin
- 82.56%
- Operating margin
- 15.26%
- Net margin
- 11.60%
Key ratios & quality
- Enterprise valuei
- 515.85M
- Altman Z-Scorei
- 7.04
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 359.11M | 299.26M | 248.23M | 242.02M | 267.84M | 321.48M | 348.88M | 418.63M |
| Gross profit | 322.73M | 256.17M | 208.90M | 202.39M | 219.53M | 266.84M | 288.81M | 345.62M |
| Selling & admin expenses | 258.53M | 198.21M | 181.02M | 194.85M | 208.67M | 211.12M | 225.09M | 266.19M |
| Research & development | 15.77M | 11.14M | 11.72M | 9.93M | 12.70M | 12.67M | 12.34M | 15.10M |
| Operating profit | -3.92M | -20.71M | -44.37M | -7.00M | -14.73M | 37.12M | 59.31M | 63.89M |
| Pretax profit | -3.40M | -25.59M | -61.54M | -12.05M | -19.75M | 30.63M | 57.29M | 66.26M |
| Tax | 26.58M | -5.00K | -12.26M | 247.00K | 206.00K | -36.81M | 15.30M | 17.68M |
| Net profit | -29.98M | -25.58M | -49.28M | -12.30M | -30.20M | 58.23M | 42.42M | 48.58M |
| Basic EPS | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.28 | -0.24 | -0.77 | -0.15 | -0.33 | 0.37 | 0.28 | 0.32 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 88.21M | 98.61M | 113.73M | 118.10M | 58.99M | 64.36M |
| Gross profit | 71.65M | 79.92M | 95.01M | 99.04M | 41.62M | 44.38M |
| Selling & admin expenses | 59.97M | 64.15M | 69.00M | 73.07M | 53.23M | 59.78M |
| Research & development | 3.33M | 3.30M | 3.70M | 4.76M | 4.14M | 2.78M |
| Operating profit | 8.25M | 12.37M | 22.19M | 21.08M | -16.05M | -18.47M |
| Pretax profit | 8.61M | 13.01M | 22.85M | 21.80M | -15.33M | -17.78M |
| Tax | 1.59M | 3.39M | 6.10M | 6.60M | -4.47M | -2.94M |
| Net profit | 7.02M | 9.62M | 16.75M | 15.19M | -10.86M | -14.84M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.05 | 0.06 | 0.11 | 0.10 | -0.07 | -0.10 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 74.05M | 123.25M | 160.62M | 148.52M | 134.20M | 164.26M | 191.89M | 277.47M |
| Cash & ST investments | 45.12M | 69.07M | 95.81M | 87.08M | 65.95M | 82.00M | 104.42M | 166.12M |
| Inventory | 15.99M | 9.10M | 10.36M | 11.39M | 13.18M | 21.02M | 23.81M | 25.34M |
| Total assets | 122.84M | 167.17M | 202.03M | 187.93M | 171.43M | 239.05M | 263.92M | 342.65M |
| Total current liabilities | 71.55M | 67.32M | 59.16M | 42.36M | 43.56M | 46.01M | 45.60M | 64.27M |
| Short-term debt | -- | 3.75M | -- | -- | -- | 1.00M | 1.00M | 1.50M |
| Long-term debt | -- | 61.91M | 47.70M | 48.13M | 48.59M | 48.10M | 17.83M | 16.47M |
| Total liabilities | 73,189,000.00 | 132,768,000.00 | 202,182,000.00 | 187,847,000.00 | 189,418,000.00 | 96,330,000.00 | 70,808,000.00 | 86,105,000.00 |
| Total equity | 49.66M | 34.40M | -150.00K | 82.00K | -17.99M | 142.72M | 193.11M | 256.55M |
| Retained earnings | -76.56M | -102.14M | -151.42M | -161.71M | -191.91M | -133.68M | -91.26M | -42.68M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 200.11M | 220.88M | 254.10M | 277.47M | 240.33M | 205.37M |
| Cash & ST investments | 106.43M | 118.87M | 142.08M | 166.12M | 159.77M | 135.84M |
| Inventory | 24.07M | 24.89M | 26.50M | 25.34M | 26.23M | 20.93M |
| Total assets | 270.42M | 291.11M | 318.99M | 342.65M | 308.68M | 281.00M |
| Total current liabilities | 42.62M | 50.29M | 57.68M | 64.27M | 44.55M | 38.50M |
| Short-term debt | 1.13M | 1.25M | 1.38M | 1.50M | 1.50M | 1.50M |
| Long-term debt | 17.53M | 17.21M | 16.84M | 16.47M | 16.09M | 15.71M |
| Total liabilities | 67,644,000.00 | 74,485,000.00 | 80,042,000.00 | 86,105,000.00 | 65,740,000.00 | 64,995,000.00 |
| Total equity | 202.78M | 216.62M | 238.95M | 256.55M | 242.94M | 216.00M |
| Retained earnings | -84.24M | -74.62M | -57.87M | -42.68M | -53.54M | -68.38M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 35.80M | -39.41M | -30.26M | -1.98M | -17.89M | 26.78M | 66.20M | 74.00M |
| Depreciation & amortization | 6.92M | 7.59M | 6.86M | 5.18M | 4.05M | 3.43M | 6.04M | 14.88M |
| Free cash flow | 26.38M | -41.16M | -34.49M | -5.20M | -19.41M | 24.79M | 64.52M | 72.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -12.49M | -1.47M | -2.33M | -4.75M | -1.19M | 0 | -2.64M | -3.12M |
| Ending cash balance | 45.12M | 69.07M | 95.81M | 87.08M | 65.95M | 82.00M | 104.42M | 166.12M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 5.30M | 14.42M | 29.33M | 24.96M | 1.88M | -10.02M |
| Depreciation & amortization | 3.20M | 3.17M | 5.29M | 3.22M | 1.62M | 1.53M |
| Free cash flow | 4.92M | 14.20M | 25.41M | 28.44M | 1.31M | -10.72M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -2.46M | -526.00K | -83.00K | -51.00K | -1.90M | -12.60M |
| Ending cash balance | 106.43M | 118.87M | 142.08M | 166.12M | 159.77M | 135.84M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -48.57 | -60.87 | -486.62 | -- | -- | 89.47 | 25.26 | 21.61 |
| ROA %i | -24.56 | -17.64 | -45.14 | -5.27 | -16.81 | 27.19 | 16.87 | 16.02 |
| ROIC %i | -48.57 | -23.76 | -115.85 | -- | -- | 55.01 | 21.38 | 19.97 |
| 5-year avg ROE %i | 10.37 | -3.33 | -66.86 | -- | -- | -- | -- | -- |
| EBIT margin %i | -1.09 | -6.92 | -17.87 | -1.96 | -9.32 | 11.54 | 16.71 | 15.26 |
| FCF / sales %i | 7.35 | -- | -- | -- | -- | 7.71 | 18.49 | 17.43 |
| Current ratioi | 1.03 | 1.83 | 2.71 | 3.51 | 3.08 | 3.57 | 4.21 | 4.32 |
| Quick ratioi | 0.64 | 1.51 | 2.39 | 3.03 | 2.50 | 2.95 | 3.51 | 3.76 |
| Debt / assetsi | -- | 39.28 | 23.61 | 25.61 | 28.35 | 20.54 | 7.13 | 5.24 |
| LT debt / equityi | -- | 179.97 | -- | 58,691.46 | -- | 33.70 | 9.23 | 6.42 |
| Interest coveragei | -- | -- | -- | -1.02 | -4.98 | 5.74 | 57.95 | -- |
| Revenue CAGR (3Y) %i | 24.23 | 10.51 | -8.23 | -12.33 | -3.63 | 9.00 | 12.96 | 16.05 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 26.66 | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 22.42 | 16.73 | 19.44 | 21.61 | 13.77 | 2.88 |
| ROA %i | 16.33 | 12.34 | 14.51 | 16.02 | 10.60 | 2.18 |
| ROIC %i | 19.93 | 15.23 | 17.86 | 19.97 | 12.74 | 2.66 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.21 | 11.61 | 13.64 | 15.26 | 10.24 | 2.46 |
| FCF / sales %i | 18.33 | 15.78 | 17.39 | 17.43 | 17.81 | 12.51 |
| Current ratioi | 4.70 | 4.39 | 4.41 | 4.32 | 5.39 | 5.33 |
| Quick ratioi | 3.96 | 3.74 | 3.82 | 3.76 | 4.62 | 4.60 |
| Debt / assetsi | 6.90 | 6.34 | 5.71 | 5.24 | 5.70 | 6.12 |
| LT debt / equityi | 8.65 | 7.95 | 7.05 | 6.42 | 6.62 | 7.27 |
| Interest coveragei | -60.23 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Surgical is the largest reported line at 61.06% of revenue, across 2 reported segments.
- Wound follows at 38.94%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Surgical61.06%
Wound38.94%
Quote time 2026-10-08 09:59:07 · For reference only, not investment advice and not tailored to your situation.